Figure 3 | British Journal of Cancer

Figure 3

From: Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma

Figure 3

Mean change from baseline in EORTC QLQ-C30 symptom scores at each post-baseline assessment. Error bars are standard error of mean (SEM). Each treatment cycle was 28 days, with vemurafenib administered on days 1–28 and cobimetinib administered on days 1–21, followed by a 7-day rest period. EORTC QLQ-C30=European Organisation for Research and Cancer Quality of Life Questionnaire Core 30.

Back to article page